{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:50:48Z","timestamp":1781977848878,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.biopha.2020.110135","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T05:33:38Z","timestamp":1587533618000},"page":"110135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Paradigms of vascularization in melanoma: Clinical significance and potential for therapeutic targeting"],"prefix":"10.1016","volume":"127","author":[{"given":"Peace","family":"Mabeta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110135_bib0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110135_bib0010","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7196\/SAMJ.2019.v109i4.13565","article-title":"The incidence of melanoma in South Africa: an exploratory analysis of National Cancer registry data from 2005 to 2013 with a specific focus on melanoma in black Africans","volume":"109","author":"Tod","year":"2019","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.biopha.2020.110135_bib0020","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jid.2018.12.006","article-title":"Trends in melanoma incidence rates in eight susceptible populations through 2015","volume":"139","author":"Olsen","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2020.110135_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/19381980.2016.1267077","article-title":"Cutaneous malignant melanoma incidences analyzed worldwide by sex, age, and skin type over personal Ultraviolet-B dose shows no role for sunburn but implies one for Vitamin D3","volume":"9","author":"Godar","year":"2017","journal-title":"Dermatoendocrinol."},{"key":"10.1016\/j.biopha.2020.110135_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/med.21404","article-title":"Metastatic melanoma: insights into the evolution of the treatments and future challenges","volume":"37","author":"Millet","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2020.110135_bib0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10555-017-9663-3","article-title":"The biology of uveal melanoma","volume":"36","author":"Amaro","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2020.110135_bib0040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/cancers3010126","article-title":"Decoding melanoma metastasis","volume":"3","author":"Damsky","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2020.110135_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jocn.2018.10.068","article-title":"Expression of cancer stem cell markers in metastatic melanoma to the brain","volume":"60","author":"Wickremesekera","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.biopha.2020.110135_bib0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcell.2019.00016","article-title":"Meeting the challenge of targeting cancer stem cells","volume":"7","author":"Turdo","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2020.110135_bib0055","first-page":"81","article-title":"Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma","volume":"14","author":"Ribatti","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2020.110135_bib0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc1092","article-title":"Angiogenesis: vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma","volume":"3","author":"Hendrix","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007890-196609000-00032","article-title":"The growth of the blood supply to melanoma transplants in the hamster cheek pouch","volume":"4","author":"Warren","year":"1966","journal-title":"Transplant."},{"key":"10.1016\/j.biopha.2020.110135_bib0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/1097-0142(197607)38:1<187::AID-CNCR2820380129>3.0.CO;2-D","article-title":"Melanoma. Tumor angiogenesis and human neoplasia","volume":"38","author":"Hubler","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0075","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00008390-199708001-00005","article-title":"Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis","volume":"7","author":"Erhard","year":"1997","journal-title":"Melanoma Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0560.1997.tb01583.x","article-title":"Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase","volume":"24","author":"Marcoval","year":"1997","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0085","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0277-5379(86)90322-6","article-title":"Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study","volume":"22","author":"Srivastava","year":"1986","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0090","first-page":"647","article-title":"Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors","volume":"75","author":"Weninger","year":"1996","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/145749690209100206","article-title":"Prognosis of primary melanoma","volume":"91","author":"Ilmonen","year":"2002","journal-title":"Scand. J. Surg."},{"key":"10.1016\/j.biopha.2020.110135_bib0100","first-page":"172","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis","volume":"56","author":"Claffey","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0105","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1523-1747.2000.00199.x","article-title":"Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor","volume":"115","author":"Lacal","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2020.110135_bib0110","first-page":"4932","article-title":"Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts","volume":"60","author":"Rofstad","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/02713683.2010.534573","article-title":"VEGF as a biomarker for metastatic uveal melanoma in humans","volume":"36","author":"Barak","year":"2011","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.0.CO;2-E","article-title":"Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL\u20108, PDGF and angiostatin in relation to vascular density of xenografts in vivo","volume":"86","author":"Westphal","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0125","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2020.110135_bib0130","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0002-9440(10)64922-X","article-title":"Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression","volume":"160","author":"Straume","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0140","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/sj.onc.1206457","article-title":"Angiogenesis, lymphangiogenesis, and melanoma metastasis","volume":"22","author":"Streit","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2020.110135_bib0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2018.36.5_suppl.182","article-title":"Comprehensive immune and mutational profile of melanoma","volume":"36","author":"Conroy","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0150","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2018.36.15_suppl.3025","article-title":"Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (IO) therapy","volume":"36","author":"Carleton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1015591624171","article-title":"Molecular determinants of human uveal melanoma invasion and metastasis","volume":"19","author":"Seftor","year":"2002","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.biopha.2020.110135_bib0165","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/sj.eye.6702783","article-title":"Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography","volume":"22","author":"Frenkel","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2020.110135_bib0170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0463.2004.apm11207-0810.x","article-title":"Vasculogenic mimicry","volume":"112","author":"Folberg","year":"2004","journal-title":"APMIS"},{"key":"10.1016\/j.biopha.2020.110135_bib0175","doi-asserted-by":"crossref","first-page":"9851","DOI":"10.1158\/0008-5472.CAN-05-2172","article-title":"Focal adhesion kinase promotes the aggressive melanoma phenotype","volume":"65","author":"Hess","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0180","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0002-9440(10)63899-0","article-title":"Differential regulation of EphA2 in normal and malignant cells","volume":"162","author":"Walker-Daniels","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0185","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-14-1855","article-title":"Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma","volume":"75","author":"Schnegg","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0190","doi-asserted-by":"crossref","first-page":"10340","DOI":"10.1158\/0008-5472.CAN-10-0705","article-title":"Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype","volume":"70","author":"Hardy","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10238-012-0190-9","article-title":"The involvement of Notch signaling in melanoma vasculogenic mimicry","volume":"13","author":"Vartanian","year":"2013","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2020.110135_bib0200","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/1078-0432.CCR-11-3237","article-title":"Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications","volume":"18","author":"Kirschmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14728222.11.4.497","article-title":"Targeting Nodal in malignant melanoma cells","volume":"11","author":"Postovit","year":"2007","journal-title":"Expert Opin. Ther. Tar."},{"key":"10.1016\/j.biopha.2020.110135_bib0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/labinvest.2016.107","article-title":"Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells","volume":"97","author":"Hendrix","year":"2017","journal-title":"Lab. Investig."},{"key":"10.1016\/j.biopha.2020.110135_bib0215","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1541-7786.MCR-14-0077","article-title":"Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma","volume":"13","author":"Hardy","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0220","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/0008-5472.CAN-05-3589","article-title":"Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase\/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2007.10.027","article-title":"Notch and PI3K-AKT pathways intertwined","volume":"12","author":"Gutierrez","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2020.110135_bib0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2045-824X-3-2","article-title":"Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity","volume":"3","author":"Funahashi","year":"2011","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.biopha.2020.110135_bib0235","first-page":"4757","article-title":"Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry","volume":"63","author":"Hess","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0240","first-page":"6322","article-title":"Cooperative interactions of laminin 5 \u03b32 chain, matrix metalloproteinase-2, and membrane type-1-matrix\/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma","volume":"61","author":"Seftor","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jcmm.12496","article-title":"Advanced research on vasculogenic mimicry in cancer","volume":"19","author":"Qiao","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2020.110135_bib0250","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/cbt.5.2.2510","article-title":"VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry","volume":"5","author":"Hess","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2020.110135_bib0255","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-019-05482-8","article-title":"Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast","volume":"179","author":"Mitra","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2020.110135_bib0260","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jcb.21855","article-title":"Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma","volume":"105","author":"Demou","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2020.110135_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2353\/ajpath.2007.060302","article-title":"Alternative vascularization mechanisms in cancer: pathology and therapeutic implications","volume":"170","author":"D\u00f6me","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0270","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10456-016-9500-2","article-title":"Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis","volume":"19","author":"Yang","year":"2016","journal-title":"Angiogenesis"},{"key":"10.1016\/j.biopha.2020.110135_bib0275","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.21873\/anticanres.11424","article-title":"Immunohistochemical study of vasculogenic mimicry and angiogenesis in melanocytic tumors of the eye and the periocular area","volume":"37","author":"Spiliopoulos","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0280","first-page":"693","article-title":"Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma","volume":"16","author":"Sun","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2020.110135_bib0285","first-page":"473","article-title":"Prognostic significance of periodic acid-schiff-positive patterns in primary cutaneous melanoma","volume":"7","author":"Warso","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0290","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/path.988","article-title":"PAS\u2010positive loops and networks as a prognostic indicator in cutaneous malignant melanoma","volume":"195","author":"Thies","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0295","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1016\/j.ejca.2013.07.148","article-title":"Tumour vasculogenic mimicry is associatedwith poor prognosis of human cancer patients: a systemic review and meta-analysis","volume":"49","author":"Cao","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0300","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1007\/DCR.0b013e3181beb4ff","article-title":"Prognostic role of vasculogenic mimicry in colorectal cancer","volume":"52","author":"Baeten","year":"2009","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.biopha.2020.110135_bib0305","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0959-8049(16)61191-7","article-title":"The role of vasculogenic mimicry in small cell lung cancer","volume":"61","author":"Williamson","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0310","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2013.226","article-title":"Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors","volume":"27","author":"Lezcano","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-9966-31-16","article-title":"Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis","volume":"31","author":"Xu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0320","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-6420(93)31470-3","article-title":"The prognostic value of tumor blood vessel morphology in primary uveal melanoma","volume":"100","author":"Folberg","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2020.110135_bib0325","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/sj.onc.1206447","article-title":"Molecular plasticity of human melanoma cells","volume":"22","author":"Hendrix","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2020.110135_bib0330","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejphar.2017.11.019","article-title":"Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes","volume":"818","author":"Han","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110135_bib0335","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2147\/CMAR.S164675","article-title":"Overview of advances in vasculogenic mimicry\u2013a potential target for tumor therapy","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0340","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1158\/1535-7163.MCT-13-1060","article-title":"Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma","volume":"13","author":"Meng","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2020.110135_bib0345","doi-asserted-by":"crossref","first-page":"e57160","DOI":"10.1371\/journal.pone.0057160","article-title":"Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma","volume":"8","author":"Itzhaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110135_bib0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-12-242","article-title":"The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts","volume":"12","author":"Milanovi\u0107","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0355","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3892\/ijo.2014.2500","article-title":"Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE\u2011cadherin\/EphA2\/MMP9\/MMP2 expression","volume":"45","author":"Guo","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-019-0785-4","article-title":"Downregulation of Nodal inhibits metastatic progression in retinoblastoma","volume":"7","author":"Asnaghi","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.biopha.2020.110135_bib0365","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1525-1438.2007.01034.x","article-title":"Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo","volume":"18","author":"Su","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0370","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/cncr.30286","article-title":"A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)","volume":"122","author":"Makker","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2020.01.042","article-title":"Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: the SIERRA open-label phase Ib trial","author":"Coleman","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0380","series-title":"Patients with Advanced Cancers","article-title":"Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent","author":"Tolcher","year":"2017"},{"key":"10.1016\/j.biopha.2020.110135_bib0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/21678707.2015.999665","article-title":"Panobinostat for the treatment of multiple myeloma","author":"Surati","year":"2015","journal-title":"Expert Opin. Orphan D."},{"key":"10.1016\/j.biopha.2020.110135_bib0390","first-page":"887","article-title":"Current advance of therapeutic agents in clinical trials potentially targeting tumor plasticity","author":"Wang","year":"2019","journal-title":"9 Front. Oncol"},{"key":"10.1016\/j.biopha.2020.110135_bib0395","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2020.110135_bib0400","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","article-title":"Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"32","author":"Rodon","year":"2014","journal-title":"Invest. New Drug."},{"key":"10.1016\/j.biopha.2020.110135_bib0405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10456-016-9500-2","article-title":"Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis","volume":"19","author":"Yang","year":"2016","journal-title":"Angiogenesis."},{"key":"10.1016\/j.biopha.2020.110135_bib0410","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/med.21496","article-title":"Potential lymphangiogenesis therapies: learning from current antiangiogenesis therapies\u2014a review","volume":"38","author":"Yamakawa","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2020.110135_bib0415","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3677","article-title":"Lymphangiogenesis and lymphatic vessel remodelling in cancer","volume":"14","author":"Stacker","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0420","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ar.20736","article-title":"Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma","volume":"291","author":"Liu","year":"2008","journal-title":"Anat. Rec. Adv. Integr. Anat. Evol. Biol."},{"key":"10.1016\/j.biopha.2020.110135_bib0425","first-page":"1","article-title":"Survival prediction in patients with cutaneous melanoma by tumour lymphangiogenesis","author":"\u0160piri\u0107","year":"2019","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.biopha.2020.110135_bib0430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.canlet.2013.12.001","article-title":"Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis","volume":"346","author":"Rui-Cheng","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2020.110135_bib0435","first-page":"139","article-title":"HIF-1\u03b1 contributes to tube malformation of human lymphatic endothelial cells by upregulating VEGFR-3","volume":"54","author":"Han","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0440","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bjps.2017.08.032","article-title":"Lymphatic vessel density and VEGF-C expression as independent predictors of melanoma metastases: methodological issues","volume":"71","author":"Ayubi","year":"2018","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"10.1016\/j.biopha.2020.110135_bib0445","first-page":"5962","article-title":"Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma","volume":"9","author":"Goydos","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0450","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1073\/pnas.95.2.548","article-title":"Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)","volume":"95","author":"Achen","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2020.110135_bib0455","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/1066896915583694","article-title":"Significance of vascular endothelial growth factor (VEGF)-C and VEGF-D in the progression of cutaneous melanoma","volume":"23","author":"\u0160piri\u0107","year":"2015","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0460","series-title":"Introduction to Cancer Metastasis","first-page":"235","article-title":"Lymph node metastasis","author":"Nathanson","year":"2017"},{"key":"10.1016\/j.biopha.2020.110135_bib0465","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1549-8719.2010.00074.x","article-title":"CCR7 mediates directed growth of melanomas towards lymphatics","volume":"18","author":"Emmett","year":"2011","journal-title":"Microcirculation"},{"key":"10.1016\/j.biopha.2020.110135_bib0470","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00403-012-1222-8","article-title":"Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10?","volume":"304","author":"K\u00fchnelt-Leddihn","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.biopha.2020.110135_bib0475","first-page":"12533","article-title":"Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC","volume":"8","author":"Chi","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2020.110135_bib0480","series-title":"Tumor Angiogenesis: A Key Target for Cancer Therapy","first-page":"135","article-title":"Angiopoietins and tie receptors in lymphangiogenesis and tumor metastasis","author":"He","year":"2019"},{"key":"10.1016\/j.biopha.2020.110135_bib0485","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2015.12.011","article-title":"Tumor lymphangiogenesis and new drug development","volume":"99","author":"Dieterich","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2020.110135_bib0490","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.2524","article-title":"A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors","author":"Falchook","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110135_bib0495","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00280-016-3134-3","article-title":"Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856\/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer","volume":"78","author":"Saif","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110135_bib0500","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.31172","article-title":"Phase 2 and biomarker study of trebananib, an angiopoietin\u2010blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma","volume":"124","author":"Reardon","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2020.110135_bib0505","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/221155281120100006","article-title":"Angiopoietin-2 axis inhibitors: current status and future considerations for cancer therapy","volume":"2","author":"Molnar","year":"2013","journal-title":"Curr. Angiogenes."},{"issue":"34","key":"10.1016\/j.biopha.2020.110135_bib0510","doi-asserted-by":"crossref","first-page":"56210","DOI":"10.18632\/oncotarget.14813","article-title":"Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat","volume":"8","author":"Rivera","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2020.110135_bib0515","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2016.70.5350","article-title":"Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of Abexinostat plus Pazopanib in advanced solid tumor malignancies","volume":"35","author":"Aggarwal","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220303279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220303279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:52:05Z","timestamp":1760097125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220303279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":103,"alternative-id":["S0753332220303279"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110135","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradigms of vascularization in melanoma: Clinical significance and potential for therapeutic targeting","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110135"}}